Dinesh Rao, MD
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $9,500 of the $13,589 with a category attached, or 69.9%. Laser Specialty Medical, LLC accounts for 69.9% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2020 at $4,147 and has fallen 80.0% since, to $831 in 2025.
Across 167 payments — averaging $81.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Laser Specialty Medical, LLC$10K
- Pfizer$613
- Astellas Pharma US Inc$438
- Axonics, Inc.$352
- Coloplast$321
- Ferring Pharmaceuticals Inc.$252
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,59026%
- Education$4984%
- Ownership interest$9,50070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Laser Specialty Medical, LLC | 3 | $9,500 |
| Pfizer | 27 | $613 |
| Astellas Pharma US Inc | 13 | $438 |
| Axonics, Inc. | 13 | $352 |
| Coloplast | 13 | $321 |
| Ferring Pharmaceuticals Inc. | 8 | $252 |
| Myriad Genetic Laboratories, Inc. | 11 | $170 |
| Johnson & Johnson(2 entities) | 8 | $164 |
| Boston Scientific | 7 | $151 |
| Sumitomo Pharma America, Inc. | 8 | $146 |
| Foundation Medicine, Inc. | 2 | $140 |
| Urogen Pharma, Inc. | 6 | $138 |
| Bioprotect Medical, Inc. | 1 | $130 |
| Integra Lifesciences Corporation | 1 | $89 |
| Teleflex LLC | 2 | $86 |
| AbbVie | 6 | $84 |
| 180 Medical, Inc. | 3 | $79 |
| Accord Healthcare, Inc. | 2 | $76 |
| Novartis | 3 | $71 |
| Healthtronics Stone Solutions, LLC | 1 | $63 |
| Bayer | 3 | $61 |
| Dendreon Pharmaceuticals LLC | 3 | $59 |
| Merck | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Urovant Sciences Inc | 2 | $35 |
| Blue Earth Diagnostics | 2 | $34 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| Baxter Healthcare | 1 | $27 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| Photocure Inc | 1 | $22 |
| Telix Pharmaceuticals | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Ambu Inc. | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $13 |
| Dentsply IH Inc. | 1 | $13 |
| Cook Medical LLC | 1 | $11 |
| Angiodynamics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,589 in reported general payments places this provider in the 80th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 253 | $277,475 |
| MyrbetriqMirabegron | 252 | $264,667 |
| Tamsulosin Hcl | 1,685 | $27,154 |
| Mirabegron ErMirabegron | 29 | $15,856 |
| Methenamine Hippurate | 231 | $14,935 |
| Solifenacin Succinate | 98 | $12,152 |
| Potassium Citrate ErPotassium Citrate | 118 | $10,936 |
| Finasteride | 518 | $8,198 |
| Dutasteride | 80 | $3,614 |
| NitrofurantoinNitrofurantoin Macrocrystal | 70 | $3,483 |
| Oxybutynin Chloride ErOxybutynin Chloride | 117 | $3,304 |
| Silodosin | 32 | $2,691 |
| Testosterone Cypionate | 43 | $2,551 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 185 | $2,489 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 63 | $1,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $146 | $277,475253 claims |
| Astellas Pharma US IncMyrbetriq | $438 | $264,667252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 urology providers in Florida.
Other urology in Ocala
- Harvey TaubOcala$208K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.